2 domains / 4 areas / 3 specializations
Beckley Foundation
Data updated
The Beckley Foundation is a UK-based non-profit founded in 1998 and based in Oxford, with a global remit focused on psychedelic research and drug policy reform. It works through scientific and policy programmes and collaborates with researchers, political leaders, and institutions internationally. Its website describes its purpose as investigating psychoactive substances and developing evidence-based drug policies grounded in health, harm reduction, cost-effectiveness, and human rights.
In psychedelic medicine and drug policy, the Beckley Foundation functions as a research and reform organization rather than a patient service group. Current documented work includes the Beckley/Imperial research programme, new collaboration with King’s College London on LSD and mystical experience research, and policy outputs such as Roadmaps to Regulation: MDMA, which argues for decriminalization and a strictly regulated legal market. This makes it relevant for researchers, clinicians, funders, and policy groups interested in clinical evidence, regulatory models, and translating psychedelic science into access and reform discussions.
Foundations & Philanthropy Snapshot
Psychedelic-Specific FoundationsClassification
Public Charity / Non-Profit
Geography
Global
Coverage
Global
Last Verified
Apr 10, 2026
Funding Focus Areas
Support Types
Philanthropy Notes
Beckley is publicly positioned as a funder and convenor of psychedelic science and policy initiatives.
Verification
Verified
Psychedelic Focus
Explicit Psychedelic Focus
Engagement Status
Active
Recorded Funding Activities
Academic and policy research collaborations
Date unknown
Grant Funding - Psychedelic and drug-policy research support
Beckley Foundation websiteJan 1, 2008
program-funding - Establishment of the Beckley/Imperial Psychedelic Research Programme (Amanda Feilding with David Nutt / Robin Carhart-Harris) - undisclosed
Long-running collaboration co-directed by Beckley Foundation founder Amanda Feilding; formalised when Nutt moved to Imperial in 2009.
The Beckley/Imperial Psychedelic Research ProgrammeJan 1, 2016
program-funding - First-ever neuroimaging study of LSD (results in PNAS) - undisclosed
Landmark LSD brain-imaging study conducted under the Beckley/Imperial programme.
The Beckley/Imperial Psychedelic Research ProgrammeJan 1, 2016
program-funding - Psilocybin feasibility study for treatment-resistant depression - undisclosed
Found 67% remission at one week; this pilot helped attract subsequent UK Medical Research Council funding.
The Beckley/Imperial Psychedelic Research ProgrammeQuick Facts
- HQ
- United Kingdom
- Website
- Visit